FY2025 · ended Dec 31, 2025 · Revenue $36.75B, +10.0% YoY · Filed Feb 13, 2026
Amgen Inc. (AMGN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $36.8 billion and net income of $7.7 billion. Free cash flow was $8.1 billion. As of Sep 30, 2026 it held $25.8 billion in cash and investments and $54.0 billion in total debt.
Revenue (TTM)
$38.90B
+8.2% vs year-ago TTM
Net income (TTM)
$9.39B
+34.1% vs year-ago TTM
Operating cash flow (TTM)
$12.04B
-8.3% vs year-ago TTM
Free cash flow (TTM)
$9.58B
-17.0% vs year-ago TTM
EPS (TTM)
$17.26
+33.4% vs year-ago TTM
Dividend per share (TTM)
$9.80
+5.8% vs year-ago TTM
Shares outstanding
539.07M
+0.3% vs prior year
Net cash
$-28.20B
as of Sep 30, 2026
Operating margin
32.4%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AMGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Thousand Oaks, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 318154
Other Biological Products, (No Diagnostic Substances) companies
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $36.8B | $33.4B | $28.2B | $26.3B | $26.0B |
| Operating income | $9.1B | $7.3B | $7.9B | $9.6B | $7.6B |
| Net income | $7.7B | $4.1B | $6.7B | $6.6B | $5.9B |
| Diluted EPS | $14.23 | $7.56 | $12.49 | $12.11 | $10.28 |
| Operating cash flow | $10.0B | $11.5B | $8.5B | $9.7B | $9.3B |
| Free cash flow | $8.1B | $10.4B | $7.4B | $8.8B | $8.4B |
| Total assets | $90.6B | $91.8B | $97.2B | $65.1B | $61.2B |
| Stockholders' equity | $8.7B | $5.9B | $6.2B | $3.7B | $6.7B |
| Cash and investments | $17.7B | $23.5B | $10.9B | $9.3B | $8.0B |
| Total debt | $55.4B | $60.9B | $65.4B | $39.6B | $34.0B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 27, 2026 | Oct 26, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K | Current report | Jul 31, 2026 | Jul 29, 2026 |
All 1000 Amgen Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.